First patent granted to Norwood Immunology

By Melissa Trudinger
Tuesday, 17 February, 2004

Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology has been granted its first patent, covering the use of GnRH analogues to increase the T cell population for the treatment of a variety of diseases.

The patent, granted in South Africa, is the first of more than 100 patent applications filed in major jurisdictions around the world covering various aspects of the immunology project.

Director of marketing Bernie Romanin said that the granted patent provided recognition of the breadth of the application of the GnRH technology.

Norwood Immunology is in the process of listing on the London Stock Exchange's AIM market. Romanin said the listing process was progressing according to plan and the company expected it to list mid-year.

Related News

Anti-inflammatory agent could decrease septic shock mortality

Researchers have discovered a naturally occurring blood protein — a type of...

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd